New York, June 29, 2020 – Privately-held Guard Medical Inc. today announces a substantial cash infusion of $5 million following the achievement of the important milestone of FDA 510k clearance for its next generation Negative Pressure Wound Therapy (NPWT) dressing NPseal™ for the treatment of closed surgical incisions. Guard Medical’s simple, innovative and cost-effective NPWT NPseal™ is a wearable dressing with an integrated pump that establishes and maintains negative pressure with just a few pinches.
“Releasing the 2nd investment tranche following the FDA clearance for our NPseal™ will allow us to accelerate market introduction and post-market clinical investigations,” stated Machiel van der Leest, CEO of Guard Medical. “We will further demonstrate the unique benefits of NPseal’s ease-of-use and cost-efficiency. Our goal is to make NPWT accessible to all patients.”
NPWT has been shown to reduce Surgical Site Infections (SSI) in a large number of peer reviewed articles, but is in limited use due to its high cost and complexity. While being easy-to-use, NPseal™ delivers the same NPWT as current more expensive and complex NPWT devices.
– end –
Guard Medical Inc. (www.guard-medical.com), a privately-held company, is developing easy-to-use and cost-effective solutions that enable prophylactic Negative Pressure Wound Therapy (NPWT) wound care of closed surgical incisions. Guard Medical’s simple NPWT technology originated with NewYork-Presbyterian and Weill Cornell Medicine in response to physicians’ identification of unmet needs related to Surgical Site Infections (SSI). Current investors include Bpifrance and Matignon Investissement et Gestion.
Guard Medical’s vision is to develop NPWT solutions for use on a wide range of surgical wound types and sizes with broad applications for infection prevention, scar mitigation and enhanced cosmesis.
For further information please contact:
Dr. Frederick Cornhill
Chief Scientific Officer, Guard Medical